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Abstract: The review is focused on the analysis of published data and the results obtained by the authors about the 
catalytic activity of antibodies (abzymes) at norm and pathology. Potential pathogenic and beneficial role of natural 
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INTRODUCTION 
After comparing the characteristics of antigen-
antibody and enzyme-substrate complexes, L. Pauling 
in 1948 came to the conclusion that antibodies, similar 
to enzymes, can catalyze chemical reactions under 
certain conditions [1]. The idea of obtaining antibodies 
with catalytic activity by immunization of animals with 
hapten-immobilized analogs of the stable transition 
states of chemical reactions belongs to B. Jenks [2] 
and was experimentally confirmed in 1986 by two 
groups researchers [3, 4]. They obtained antibodies 
possessing the ability to accelerate hydrolysis of esters 
in 1000 times. These antibodies were named as 
"catalytically active antibodies" or "artificial abzymes". 
These antibodies were named as "catalytically active 
antibodies" or "artificial abzymes". Combining the 
immunization of animals with the technology of 
monoclonal antibodies allowed to obtain abzymes, are 
capable of catalyzing more than 100 chemical 
reactions [5]. All this, gave a reason to speak about a 
new biological discipline - abzymology. 
New stimulus for enzymology has done in 1989 by a 
group of S. Paul, when they purified from a blood 
serum of bronchial asthma patients antibodies, are 
capable of hydrolyzing vasoactive intestinal 
neuropeptide (VIP) [6]. During the following years it 
was revealed that many human diseases (autoimmune, 
viral, cancer) are associated with appear in a blood 
serum of patients of different enzymes with peptidase, 
protease, DNase, RNase and others activities (see 
reviews [7-9]). Such catalytically active antibodies are 
called "natural" abzymes. Since abzymes were not 
detected in the body of healthy people, it was 
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suggested that their production is linked with 
pathological processes. The suggestion about 
existence of natural abzymes in norm has done, when 
was shown that colostrum and milk of healthy women 
could contain secretory immunoglobulin A (sIgA), 
possessing the ability to catalyze the casein 
phosphorylation [10]. During the following years in 
colostrum and milk of humans were revealed different 
antibody isotypes, are capable of hydrolysing DNA [11-
14], RNA [14-15], nucleotides [16], proteins [17, 18], 
polysaccharides [19], as well as to phosphorylate of 
proteins [20-22], lipids [23-26] and polysaccharides 
[27]. 
Next studies revealed that natural abzymes are 
present in blood serum of healthy humans [28 - 31]. 
Catalytical activity of such abzymes are directed toward 
a different autological antigens. 
The ability to catalyze the reaction between oxygen 
radicals and water, which leads to the formation of 
hydrogen peroxide and ozone was shown as the 
property of all classes of immunoglobulins of mammals. 
This activity is determined by amino acid residues of 
tryptophan (Trp 36 and Trp37), which is a constitutive 
part of 99% of all immunoglobulin molecules [32 - 34] 
and don’t depend on antibody-antigen specificity or 
their origin. Similar catalytic activity was also detected 
for some proteins with non imunoglobuline nature - 
beta-galactosidase and chicken egg ovalbumin [33, 
34]. Since variable regions are not involved in catalysis, 
it is believed that the oxidoreductase activity of 
antibodies not belongs to abzymatic activity. 
PROTEASE-LAKE ABZYMES (PROTABZYMES)  
Abzymes, possessing protease activity were named 
as “protabzymes”. As was mentioned above, 
protabzymes, capable of hydrolyzing intestinal 
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vasoactive peptide (VIP), were firstly isolated from 
blood serum of patients with bronchial asthma in 1989 
[6]. Also has been developed some criteria of proving 
of abzymatic activity.  
This is including such requirements:  
1 - high homogeneity of immunoglobulin samples,  
2 - affinity of antibodies to reaction substrates, 
3 - catalytic activity of the antibody Fab-fragments,  
4 - saving of the capability of hydrolyzing substrate 
after dissociation of immune complex  
Another example of protabzymes, associated to 
human autoimmune diseases is thyroglobulin-
hydrolyzing abzymes, isolated from blood serum of 
patients with acute Hashimoto thyroiditis [9, 35]. The 
use of radioactive labeled thyroglobulin allowed to find 
that abzymes are capable of hydrolyzing of this protein 
to low molecular weight peptides. The Km value of this 
reaction was in the order of nanomolar concentrations 
of thyroglobulin. These abzymes catalyzed hydrolysis 
of a synthetic tripeptide methylcoumarin, but with 
essentially lowest activity. Catalytic activity toward 
tripeptide methylcoumarin has been shown also for a 
human myeloma Bence-Jones proteins (multimeric 
light chains of immunoglobulins) [36, 37]. It was shown, 
that such proteins are capable of hydrolyzing synthetic 
chromogenic substrates of trypsin (chromasines TRY 
and BApNa). pH optimum of these reactions is 8,4, and 
Km value is in range of 140-730 μM (for TRY) and 18-
27 μM (for BApNa). Fact that protabzymes can play an 
essential role in the development of pathological 
processes in autoimmune diseases has forced 
researchers to search for new abzymes with catalytic 
activity and with unknown substrate specificity. As a 
result of this investigation have been discovered IgGs, 
isolated from cerebrospinal fluid and blood serum of 
multiple sclerosis patients with hydrolyzing activity 
toward myelin basic protein (MBP) [38 - 40]. Since the 
destruction of the MBP causes demyelination of axons, 
it is reasonable to assume that these sabzymes are 
involved in development of pathology of multiple 
sclerosis. 
Followed studies revealed that protabzymes is 
hallmark to factor VIII - resistant hemophilia A patients 
[41]. Following studies revealed that protabzymes is a 
hallmark for factor VIII - resistant hemophilia A patients 
[41]. Abzym’s activity level in blood serum significantly 
correlated with the resistance of these patients to effect 
of FVIII therapeutic drugs. Protabzymes also was fond 
in human colostrum and milk of healthy women. As 
substrate of there activity could serve human milk 
casein [42], histone H1 and myelin basic protein [43, 
44]. Hydrolysis of protein antigens by a mechanism 
similar to serine proteases is typical to abzymes of 
healthy humans [45]. It was shown that antibodies 
isolated from blood serum of healthy donors, belong to 
the IgM class and are capable of hydrolyzing some 
viral and bacterial superantigens [29, 30]. Also, it was 
found, that IgM and IgG from blood serum of elderly 
people can hydrolyze neurotoxic beta-amyloid peptide, 
which is involved in the development of Alzheimer's 
disease. According to this data, abzymes detected in 
healthy humans possesses preferentially a protective 
function. 
PROTEIN KINASE-LIKE ABZYMES 
 In 1991 we described for the first time the capability 
of antibodies having ability to catalyze protein 
phosphorylation [46]. It was found that 
electrophoretically homogeneous sIgA, purified from 
milk of healthy mothers are capable of phosphorylate 
human milk casein on a serine residues. This work has 
stimulated subsequent study of human milk abzymes. 
As was mentioned above, the main problem of natural 
abzyme is contamination of antibody samples with 
native enzyme possessing similar catalytic activity. To 
satisfy criteria of purity of antibodies which belong to 
abzymes, there was developed a number of purification 
schemes [20 - 22]. Usually this purification includes a 
multistep procedure consisting with affinity and ion 
exchange chromatography. 
The method of sIgA-abzyme isolation we have 
developed is based on higher affinity of catalytically 
active fraction of sIgA to Protein A-Sepharose in 
compare with catalytically inactive antibodies [10]. 
Purified antibodies were additionally separated by ion-
exchange chromatography on DEAE-sorbent. As a 
next step, electrophoretically homogeneous 
preparations of sIgA were performed by 
chromatography on matrix containing immobilized of 
protein kinase reaction - ATP-sepharose and casein-
sepharose. To determine the localization of catalytic 
center into the molecule of the catalytically active sIgA 
we used two reactive ATP analogues - dialdehide 
derivative [-32P] ATP (oxyATP) and alkylating 
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derivative o [-32P] ATP (RCl-ATP) [20]. This approach 
allows detecting ATP-binding sites preferentially 
located on light chain of a sIgA molecule. The high 
affinity of the light chain to ATP was also confirmed by 
affinity chromatography of sIgA-abzymes on ATP-
sepharose under conditions of dissociation of 
immunoglobulin polypeptide chains [10]. It was found 
that IgA-abzymes can phosphorylate variety of human 
milk proteins, and under certain conditions, have 
capacity to autophosphorylation [21-22]. Some 
unexpected results were obtained when for 
phosphorylation reaction were used other nucleotide 
triphosphates. It was found that all purine and 
pyrimidine nucleotide triphosphates can serve as the 
substrates of protein kinase activity of sIgA-Abzyme 
[20]. This date demonstrate the unique properties of 
abzymes in comparison to common protein kinases, 
which are capable of using as a phosphate donor ATP 
or GTP. Thus, sIgA-abzymes are classified as protein 
kinases, which have multi substrate specificity and 
properties, which are significantly different from other 
protein kinases.  
LIPID KINASE-LIKE ABZYMES 
Lipid kinase activity of abzymes was discovered 
during analysis of the phosphorylated products of a 
protein kinase activity of the sIgA-abzymes [23, 24]. 
Phosphorylated products, labeled with radioactive 
phosphorus, were isolated from the reaction mixture 
with chloroform-methanol solution and separated into 
three fractions, using thin layer chromatography. 
Following studies showed that isolated phospholipids 
form complexes with sIgA-abzymes [25]. Detailed 
analysis of the structure of phosphorylated lipid was 
carried out in G. Nevinsky lab. of Institute of Chemical 
Biology and Fundamental Medicine [26, 27]. To do this 
the authors used combined methods of enzymatic and 
chemical degradation, including processing with 
neuraminidase, alkaline hydrolysis in methanol and 
oxidation with periodic acid. The authors concluded 
that milk sIgA-abzymes can use as alternative to 
casein also two minor milk glycolipids, containing one 
sialic acid and 4-5 fatty acid residues.  
NUCLEOTIDE-HYDROLYSING ABZYMES 
Nucleotide-hydrolyzing activity in first time was 
discovered to sIgA [10], but in detail it was studied to 
human milk IgGs [16]. To purification of these abzymes 
was used earlier developed schema including 
chromatography human milk proteins on columns with 
Protein A-Sepharose, DEAE-cellulose, immobilized on 
sepharose monospecific antibodies to human IgGs and 
ATP-Sepharose. It was shown that electrophoretically 
homogeneous human milk IgGs and their Fab-
fragments are capable of hydrolyzing ribonucleotide 
and deoxyribonucleotide 5'-mono-, two- and 
triphosphates. To detection of position catalytically 
active sites located in the IgG molecule was used 
method of affinity modification of IgG molecules with 
alkylating analogues of radiolabeled ATP. It was 
discovered that the ATP-binding site is located at light 
(L) chain of IgG molecules. It was developed an 
original method of determining the catalytic activity of 
abzymes, based on the nucleotide-hydrolyzing activity 
of IgG in polyacrylamide gels after their separation by 
electrophoresis in denaturing conditions [16]. This 
method revealed that the nucleotide-hydrolyzing 
activity is inherent to entire molecules of IgG-abzymes 
or their oligomeric forms. Reduction of IgG with their 
subsequent dissociation to heavy and light chains 
leads to loss of catalytic activity. Based on these 
results there was concluded, that although ATP binding 
area is located on the L-chain of IgG molecules , H-
chains are also required to provide the hydrolysis 
reaction. 
Analysis of thermodynamic and kinetic parameters 
of this reaction with various nucleotides discovered that 
the lowest Km is 44 M for the hydrolysis of ATP, and 
the highest (Km = 79 mM) - for dCTP. Vmax for different 
nucleotide changes in range from 0.57 μM / min for 
dATP to 1.1 μmM / min for CTP. 
DNA-HYDROLYZING ANTIBODIES (DNA-ABZYMES) 
 It should be note, that DNA-hydrolyzing antibodies 
belong to the most studied abzymes. IgG, having 
topoisomerase activity (catalyzing breaks of one-strain 
supercoiled forms of plasmid DNA) were isolated from 
blood serum of patients with systemic lupus 
erythematosus in 1992 by team of prof. A. Gabibov 
[27]. Following studies have shown that DNA-abzymes 
also presence in blood serum of patients with various 
autoimmune diseases (scleroderma, rheumatoid 
arthritis, thyroiditis, multiple sclerosis), AIDS patients, 
radiation syndrome, hepatitis and lymphoproliferative 
types of cancer [7, 12, 39 - 50]. DNA-abzymes were 
not found in blood serum of patients with influenza, 
pneumonia, tuberculosis, tonsillitis, some cancers, as 
well as in clinically healthy individuals. It is allow to 
suggest that the DNA-abzymes may be serve as 
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pathogenic factors at some autoimmune diseases. For 
example, in serum of SLE patients, DNA-hydrolyzing 
activity level of IgG is closely correlated with the clinical 
manifestation of the disease. It was found that 
pathogenic effect of DNA-abzymes may be directly 
linked with their cytotoxicity. DNA-abzymes can induce 
a caspase-dependent apoptosis in human 
promyelocyte cells line HL-60, human T-cell lymphoma 
line Raji, transformed mouse fibroblast line L929 and 
human erythroleukemia cell line K562 in vitro [50, 51]. 
Fab-fragments of these antibodies possess the same 
activity. The mechanism of their cytotoxic activity 
remains unknown. Existing data allow to suggest that 
cytotoxic activity of DNA-abzymes could be closely 
linked with their ability to internalized by cells, their 
translocation into the nucleus that induce the DNA 
degradation. 
POLYSACCHARIDE-HYDROLYZING ABZYMES 
 The ability of antibodies to hydrolyze 
polysaccharides was firstly described in 1999 [52]. It 
was found that IgG and IgM from blood serum of 
patients with rheumatoid arthritis, multiple sclerosis, 
pyelonephritis, and some cancers are able to hydrolyze 
maltose-containing oligosaccharides, glycogen and 
similar compounds. As substrates of glycosidase 
activity of these abzymes the authors used para-
nitrophenyl-maltoseoligosaccharides with different 
lengths. Reaction products were analyzed by thin-layer 
chromatography and reverse phase HPLC separation.  
The presence of polysaccharide-hydrolyzing 
abzymes in colostrum and milk of healthy women was 
detected by the same group of researchers [22]. These 
abzymes were able to catalyze cleavage of maltose-
containing oligosaccharides, glycogen and similar 
compounds. It is shown that Fab-fragments of these 
antibodies are capable of catalyzing the similar 
reactions. 
SIALYDASE-LIKE ABZYMES (SIALIC-ABZYME) 
Cell surface sialylation is known to be tightly 
connected with tumorigenicity, invasiveness, metastatic 
potential, clearance of aged cells, while the sialylation 
of IgG molecules determines their anti-inflammatory 
properties [61]. Four sialidases – hydrolytic enzymes 
responsible for cleavage of sialic residues – were 
described in different cellular compartments [62]. We 
have found and characterized first known IgG 
antibodies possessing sialidase-like activity in blood 
serum of multiplemyeloma patients [63]. 
Immunoglobulin fractions were precipitated with 
ammonium sulfate (50% of saturation) from blood 
serum of healthy donors and MM patients, and 
screened for the presence of sialidase activity by using 
4-MUNA (2(-(4-methylumbelliferyl)-a-D-N-
acetylneuraminic acid) as substrate. High level of 
sialidase activity was detected in some MM patients, 
but not in healthy donors. Subsequent antibody 
purification by protein-G affinity chromatography and 
HPLC size exclusion chromatography at acidic 
conditions demonstrated that sialidase activity was 
attributable to IgG molecules. Sialidase activity was 
also specific for (Fab)2 fragment of IgG and blocked by 
sialidase inhibitor DANA. Sialidase activity of IgG 
molecule was also confirmed by in gel assay. Kinetic 
parameters of the catalysis reaction were described by 
Michaelis–Menten equation with Km:44.4–108 mM and 
kcat:2.7–23.1. The action of IgG possessing sialidase-
like activity on human red blood cells leads to increase 
their agglutination by the peanut agglutinin, that 
confirms their desialylation. Sialidase active IgGs were 
also detected in blood serum of the systemic lupus 
erythematosis (SLE) patients, but were not found in 
healthy donors [64]. We have found that mucin, 
isolated from bovine submandibular glands and 
conjugated with Sepharose beads could serve as a 
useful matrix for purification of sialydase active 
abzymes from blood serum of the SLE patents. That 
allowed us to develop a scheme of double-step 
chromatography purification of sialidase-like IgGs from 
human blood serum [65].  
Recently, we have created artificial sialidase 
abzyme by means of rabbit immunization with a 
synthetic hapten consisting of nonhydrolyzable inhibitor 
of sialidase reaction conjugated with bovine serum 
albumin [66]. Incubation of the apoptotic cells with both 
natural (purified from blood serum of SLE patient and 
artificial (obtained by rabbits immunization) sialidase-
like IgGs and their F(ab)2 fragments significantly 
enhanced their clearance by the macrophages [67]. We 
suggest that sialidase abzyme can serve as a 
protective agent in autoimmune patients and those 
artificial abzymes could be of therapeutic value.  
CONCLUSION 
The pathogenic or beneficial effect of catalytic 
antibodies has been directly demonstrated in numerous 
studies . This is making abzymes as essential factor in 
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immune response of human organism to self and 
others antigens.  
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